Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

Patterns and Prevention of Cardiovascular Diseases - report from EASD 2026

Oct. 16, 2026

Dr. Alexandra Kautzky-Willer presents key insights on the patterns and prevention of cardiovascular diseases at the EASD 2026 Congress. This brief highlights clinical strategies for identifying cardiovascular risk patterns, implementing targeted early preventive measures, and optimizing long-term o…

00:08:34

Advancing Cardiovascular Protection with Incretins and SGLT-2 Inhibitors: EASD-ESC Joint Session - report from EASD 2026

Oct. 16, 2026

Dr. Åke Sjöholm presents key insights from the EASD-ESC joint session on advancing cardiovascular protection with incretins and SGLT-2 inhibitors at the EASD 2026 Congress. This brief highlights clinical mechanisms, cardiorenal benefits, and combined therapeutic strategies to reduce cardiovascular …

00:08:47

Making the Connections to Reduce Risk: Cardiovascular, Renal, and Metabolic Benefits of SGLT-2 Inhibitors in T2D - report from EASD 2026

Oct. 16, 2026

Dr. Gian Paolo Fadini presents key insights into interconnected organ protection with SGLT-2 inhibitors at the EASD 2026 Congress. This brief highlights clinical evidence on the cardiovascular, renal, and metabolic benefits of SGLT2 inhibition, emphasizing strategies to reduce overall risk and opti…

00:10:58

Changing the Trajectory of Chronic Metabolic Disease: A Hepatology Perspective on GLP-1 Care & Integrating Liver Health Beyond Steatosis - report from EASD 2026

Oct. 16, 2026

Dr. Eric Lawitz presents a hepatologist's perspective on altering the trajectory of chronic metabolic disease at the EASD 2026 Congress. This brief highlights the evolving role of GLP-1-based therapies and strategies for integrating targeted liver health management beyond simple steatosis into comp…

00:05:47